Amubarvimab, previously known as BRII-196 , represents a crucial advancement in antibody development, particularly concerning its potential to block COVID-19. This targeted agent demonstrates remarkable https://bookmarks-hit.com/story26006304/amubarvimab-a-deep-dive-into-brii-196-s-prospects